B.E.C. Nordin, MD; A.G. Need, MD; H.A. Morris, PhD; M. Horowitz, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: The uncompromising title and conclusions to the article by Ott and Chesnut (1) threaten to delay the long overdue introduction of calcitriol into the management of osteoporosis. We believe no general inference about the value of calcitriol therapy can be made based on their trial. Significantly impaired calcium absorption is an important feature of many patients with osteoporosis, and we consider this impairment to be a risk factor for osteoporosis in its own right.
Impaired calcium absorption can be completely corrected with small doses (on the order of 0.25 µ daily) of calcitriol (2). Moreover, this treatment
Nordin B, Need A, Morris H, et al. Calcitriol and Osteoporosis. Ann Intern Med. 1989;111:689. doi: https://doi.org/10.7326/0003-4819-111-8-689_1
Download citation file:
Published: Ann Intern Med. 1989;111(8):689.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use